Furthermore, drug sensitivity analysis revealed the sensitivity and resistance spectrum of PLEK2 and PLEK2‐related hub genes to various small molecules and other anti‐cancer drugs, which could provide support for individualized therapies and clinical decision‐making. Here, PLEK2 is linked to cancer.